RESUMO
Post-stroke depression (PSD) is a very common complication that leads to increased physical disability, poor functional outcome, and higher mortality. Therefore, early detection and treatment are very important. Since there are currently no specific guidelines for this disorder in China, the purpose of this study was to develop PSD guidelines and provide suggestions for clinicians and related workers.
Assuntos
Humanos , Acidente Vascular Cerebral/psicologia , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/terapia , Psicoterapia , Fatores de Tempo , Índice de Gravidade de Doença , China/epidemiologia , Fatores de Risco , Guias de Prática Clínica como Assunto , Sobreviventes/psicologia , Depressão/etiologia , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/epidemiologia , Autorrelato , Reabilitação do Acidente Vascular Cerebral/normas , Antidepressivos/uso terapêuticoRESUMO
Post-stroke depression (PSD) is a very common complication that leads to increased physical disability, poor functional outcome, and higher mortality. Therefore, early detection and treatment are very important. Since there are currently no specific guidelines for this disorder in China, the purpose of this study was to develop PSD guidelines and provide suggestions for clinicians and related workers.
Assuntos
Transtorno Depressivo/diagnóstico , Transtorno Depressivo/terapia , Acidente Vascular Cerebral/psicologia , Antidepressivos/uso terapêutico , China/epidemiologia , Depressão/etiologia , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/epidemiologia , Humanos , Guias de Prática Clínica como Assunto , Psicoterapia , Fatores de Risco , Autorrelato , Índice de Gravidade de Doença , Reabilitação do Acidente Vascular Cerebral/normas , Sobreviventes/psicologia , Fatores de TempoRESUMO
Human epidermal growth factor receptor 2 (HER2) dysregulation is associated with tumorigenesis in gastric/gastroesophageal junction cancer; however, the number of patients with HER2-positive disease is unclear, possibly due to differing scoring criteria/assays. Data are also lacking for early disease. We aimed to assess the HER2-positivity rate using approved testing criteria in a large, real-life multinational population. HER2-positivity was defined as an immunohistochemistry staining score of 3+, or immunohistochemistry 2+ and HER2 amplification detected by in situ hybridization. A total of 4949 patients were enrolled and results showed that 14.2% of 4920 samples with immunohistochemistry results were HER2-positive. HER2-positivity was significantly higher in males (16.1% vs. 9.6% in females), in gastroesophageal versus stomach tumors (22.1% vs. 12.9%), in biopsy versus surgical samples (18.3% vs. 13.0%), in intestinal tumor subtypes versus diffuse (21.5% vs. 4.8%) and mixed types (21.5% vs. 8.5%) (P<0.001), in mixed versus diffuse types (8.5% vs. 4.8%), and in "other" versus diffuse types (11.7% vs. 4.8%; P=0.002). There were no significant differences between stages. Patients in the youngest age percentile had significantly lower HER2-positivity rates than patients in the remaining percentiles (9.2% vs. 15.9%, 15.7%, and 15.1%; P<0.001). HER2-positivity was highest in France (20.2%) and lowest in Hong Kong (10.4%). In conclusion, HER-EAGLE, the first study of its kind to be conducted in a large, multinational population of almost 5000 patients, gives valuable insights into the real-world HER2-positivity rate in a gastric/gastroesophageal junction cancer patient population not selected for disease stage or histology.